# Kriya Therapeutics

> Kriya Therapeutics, Inc. is a clinical-stage biopharmaceutical company founded in 2019 that
> designs, develops and manufactures one-time AAV gene therapies for chronic diseases affecting
> large patient populations. It is headquartered in Research Triangle Park (Durham, North Carolina)
> with operations in Palo Alto, California, and has raised over $900 million. Its pipeline spans
> ophthalmology (geographic atrophy, thyroid eye disease), metabolic disease (Type 1 diabetes,
> MASH/NASH) and neurology (trigeminal neuralgia), supported by in-house GMP manufacturing from 1L
> research scale to 3,000L bioreactor scale.

Kriya Therapeutics runs no developer program. It publishes no product API, no developer portal, no
API documentation, no SDKs, no CLI, no MCP server, no A2A agent card, no status page and no
/.well-known/ discovery surface. The only machine-readable surface reachable without credentials is
the WordPress REST content API behind kriyatherapeutics.com, which serves the corporate site. This
file was generated by API Evangelist from the public catalog profile at
https://github.com/api-evangelist/kriya-therapeutics — it is not published by Kriya Therapeutics.

Generated: 2026-08-04
Method: generated (no /llms.txt is published at kriyatherapeutics.com — probed 2026-08-04, HTTP 404)

## Company

- [Kriya Therapeutics](https://kriyatherapeutics.com/): Corporate home. Also reachable at kriyatx.com.
- [Pipeline](https://kriyatherapeutics.com/pipeline/): The full development pipeline across three therapeutic areas.
- [Ophthalmology](https://kriyatherapeutics.com/pipeline/ophthalmology/): Geographic atrophy, thyroid eye disease (KRIYA-586) and undisclosed programs.
- [Metabolic Disease](https://kriyatherapeutics.com/pipeline/metabolic-disease/): Type 1 diabetes, MASH/NASH and undisclosed programs.
- [Neurology](https://kriyatherapeutics.com/pipeline/neurology/): Trigeminal neuralgia and undisclosed programs.
- [Product Design](https://kriyatherapeutics.com/product-design/): Computational and experimental approach to designing gene therapy products.
- [Research & Development](https://kriyatherapeutics.com/research-development/): Discovery and translational research.
- [Platform](https://kriyatherapeutics.com/manufacturing/): In-house GMP manufacturing — 1L to 3,000L bioreactor scale, 50L/500L/3,000L GMP capacity, Akta chromatography purification, vial filling, in-house analytical characterization.
- [Team](https://kriyatherapeutics.com/our-team/): Leadership, board of directors, founders, and scientific and strategic advisors.
- [News](https://kriyatherapeutics.com/newsroom/): Press releases. Unlike most corporate sites, this archive IS machine-readable — see the API section.
- [Careers](https://kriyatherapeutics.com/careers/): Open roles.
- [Connect](https://kriyatherapeutics.com/connect/): Contact form, phone +1-833-574-9289, 1219 Shiloh Glenn Drive, Durham, NC 27703.
- [Site Map](https://kriyatherapeutics.com/site-map/): Full page index.

## Company history (from the machine-readable news archive)

- 2020-05-12 — $80M Series A financing.
- 2020-08-04 — Established internal manufacturing facility for process development.
- 2021-07-14 — $100M Series B financing.
- 2021-07-28 — Completed renovation of the scalable gene therapy manufacturing facility.
- 2022-01-26 — Licensed next-generation complement-targeted gene therapies for geographic atrophy.
- 2022-05-16 — $270M Series C financing.
- 2022-08-25 — Curt Herberts appointed President and COO.
- 2022-11-16 — Acquired Redpin Therapeutics, adding the neurology pipeline.
- 2023-07-26 — $150M Series C extension, bringing the round to over $430M.
- 2023-09-06 — Acquired Tramontane Therapeutics and launched the NASH program.
- 2023-09-27 — Exclusive license and collaboration with Everads.
- 2024-01-05 — Announced the thyroid eye disease gene therapy program.
- 2024-06-18 — Katherine Eade appointed Chief Legal Officer.
- 2024-07-08 — Scientific co-founder J. Fraser Wright, Ph.D. appointed Chief Gene Therapy Officer.
- 2024-09-12 — Positive preclinical data for KRIYA-586 (thyroid eye disease).
- 2024-11-13 — Publication of preclinical data for investigational AAV-FGF21 gene therapy.
- 2025-09-10 — $320M Series D financing.
- 2025-12-01 — Greg Di Russo, M.D. appointed Chief Medical Officer.
- 2026-01-05 — Sachiyo Minegishi appointed Chief Financial Officer.
- 2026-04-30 — Presentations at ASGCT 2026 across the gene therapy platform.
- 2026-06-29 — Selected for the FDA PreCheck Pilot Program.

## APIs

- [Kriya Therapeutics Content API](https://kriyatherapeutics.com/wp-json/): The anonymously readable WordPress REST content API behind kriyatherapeutics.com. Read-only for anonymous callers. 28 dated news items (the full press-release archive, individually addressable and date-filterable), 33 posts, 18 pages, a 304-item media library, taxonomies, cross-content search over 58 objects, and an oEmbed 1.0 provider endpoint.
- [WordPress REST API handbook](https://developer.wordpress.org/rest-api/): The upstream reference that defines the wp/v2 contract. Kriya Therapeutics publishes no API documentation of its own.

## Specs and artifacts

- [OpenAPI 3.1 (derived)](https://raw.githubusercontent.com/api-evangelist/kriya-therapeutics/refs/heads/main/openapi/kriya-therapeutics-content-openapi.yml): 25 operations derived from the live route index and verified against anonymous responses.
- [APIs.json](https://raw.githubusercontent.com/api-evangelist/kriya-therapeutics/refs/heads/main/apis.yml): The full catalog profile.
- [Authentication](https://raw.githubusercontent.com/api-evangelist/kriya-therapeutics/refs/heads/main/authentication/kriya-therapeutics-authentication.yml): Anonymous read; the site advertises NO authentication method at all.
- [Conventions](https://raw.githubusercontent.com/api-evangelist/kriya-therapeutics/refs/heads/main/conventions/kriya-therapeutics-conventions.yml): Pagination, field selection, embedding, caching, error envelope.
- [Error catalog](https://raw.githubusercontent.com/api-evangelist/kriya-therapeutics/refs/heads/main/errors/kriya-therapeutics-problem-types.yml): Live-observed error responses. Not RFC 9457 — and an unknown id returns an nginx HTML 404, not JSON.
- [Data model](https://raw.githubusercontent.com/api-evangelist/kriya-therapeutics/refs/heads/main/data-model/kriya-therapeutics-data-model.yml): Entity-relationship graph across the two custom post types.
- [Conformance](https://raw.githubusercontent.com/api-evangelist/kriya-therapeutics/refs/heads/main/conformance/kriya-therapeutics-conformance.yml): Standards this surface does and does not meet.
- [Lifecycle](https://raw.githubusercontent.com/api-evangelist/kriya-therapeutics/refs/heads/main/lifecycle/kriya-therapeutics-lifecycle.yml): No versioning policy, no deprecation policy, no SLA, no status page.
- [Well-known](https://raw.githubusercontent.com/api-evangelist/kriya-therapeutics/refs/heads/main/well-known/kriya-therapeutics-well-known.yml): Every /.well-known/ path probed on three hosts, all 404.
- [Domain security](https://raw.githubusercontent.com/api-evangelist/kriya-therapeutics/refs/heads/main/security/kriya-therapeutics-domain-security.yml): TLS 1.3, no HSTS, SPF present, no DMARC, no DNSSEC, no CAA.
- [Agent skills](https://raw.githubusercontent.com/api-evangelist/kriya-therapeutics/refs/heads/main/skills/_index.yml): Packaged operating instructions for the content API.

## Not published

- No OpenAPI, AsyncAPI, JSON Schema or GraphQL schema published by Kriya Therapeutics.
- No SDKs or client libraries on npm, PyPI or any registry; no GitHub organization (kriyatx, kriya-therapeutics and kriyatherapeutics all 404 on the GitHub API).
- No CLI, no sandbox, no Postman collection, no embedded components, no webhooks, no event/streaming surface.
- No MCP server. The site registers the WordPress Abilities API (`wp-abilities/v1`) but every route under it returns 401 to anonymous callers, so no agent capability is exposed.
- No A2A agent card at `/.well-known/agent-card.json` or `/.well-known/agent.json` (both 404 on kriyatherapeutics.com, kriyatx.com and www.kriyatherapeutics.com).
- No security.txt, no vulnerability disclosure policy, no bug bounty, no trust center, no named certifications.
- No pricing, sign-up, rate-limit policy or developer terms — there is no developer product to price or subscribe to. The Terms of Use and Privacy Policy govern the website.